Homeobox protein Hox-B13 is a protein that in humans is encoded by the HOXB13 gene.[1][2][3]
This gene encodes a transcription factor that belongs to the homeobox gene family. Genes of this family are highly conserved among vertebrates and essential for vertebrate embryonic development. This gene has been implicated in fetal skin development and cutaneous regeneration. In mice, a similar gene was shown to exhibit temporal and spatial colinearity in the main body axis of the embryo, but was not expressed in the secondary axes, which suggests functions in body patterning along the axis. This gene and other HOXB genes form a gene cluster on chromosome 17 in the 17q21-22 region.[3] Men who inherit a rare (<0.1% in a selected group of patients without clinical signs of prostate cancer) genetic variant in HOXB13 (G84E or rs138213197) have a 10-20-fold increased risk of prostate cancer.[4]
Contents |
See also [link]
References [link]
- ^ Zeltser L, Desplan C, Heintz N (Sep 1996). "Hoxb-13: a new Hox gene in a distant region of the HOXB cluster maintains colinearity". Development 122 (8): 2475–84. PMID 8756292.
- ^ Stelnicki EJ, Arbeit J, Cass DL, Saner C, Harrison M, Largman C (Jul 1998). "Modulation of the human homeobox genes PRX-2 and HOXB13 in scarless fetal wounds". J Invest Dermatol 111 (1): 57–63. DOI:10.1046/j.1523-1747.1998.00238.x. PMID 9665387.
- ^ a b "Entrez Gene: HOXB13 homeobox B13". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=10481.
- ^ Ewing C, et al (Jan 2012). "Germline mutations in HOXB13 and prostate cancer risk". New Engl J Med 366 (2): 141–9. PMID 22236224.
Further reading [link]
{{PBB_Further_reading | citations =
- Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.". Gene 138 (1-2): 171–4. DOI:10.1016/0378-1119(94)90802-8. PMID 8125298.
- Shen WF, Montgomery JC, Rozenfeld S, et al. (1997). "AbdB-like Hox proteins stabilize DNA binding by the Meis1 homeodomain proteins.". Mol. Cell. Biol. 17 (11): 6448–58. PMC 232497. PMID 9343407. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=232497.
- Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library.". Gene 200 (1-2): 149–56. DOI:10.1016/S0378-1119(97)00411-3. PMID 9373149.
- Kosaki K, Kosaki R, Suzuki T, et al. (2002). "Complete mutation analysis panel of the 39 human HOX genes.". Teratology 65 (2): 50–62. DOI:10.1002/tera.10009. PMID 11857506.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. DOI:10.1073/pnas.242603899. PMC 139241. PMID 12477932. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=139241.
- Kömüves LG, Ma XK, Stelnicki E, et al. (2004). "HOXB13 homeodomain protein is cytoplasmic throughout fetal skin development.". Dev. Dyn. 227 (2): 192–202. DOI:10.1002/dvdy.10290. PMID 12761847.
- Jung C, Kim RS, Lee SJ, et al. (2004). "HOXB13 homeodomain protein suppresses the growth of prostate cancer cells by the negative regulation of T-cell factor 4.". Cancer Res. 64 (9): 3046–51. DOI:10.1158/0008-5472.CAN-03-2614. PMID 15126340.
- Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).". Genome Res. 14 (10B): 2121–7. DOI:10.1101/gr.2596504. PMC 528928. PMID 15489334. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=528928.
- Jung C, Kim RS, Zhang HJ, et al. (2005). "HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling.". Cancer Res. 64 (24): 9185–92. DOI:10.1158/0008-5472.CAN-04-1330. PMID 15604291.
- Zhao Y, Yamashita T, Ishikawa M (2005). "Regulation of tumor invasion by HOXB13 gene overexpressed in human endometrial cancer.". Oncol. Rep. 13 (4): 721–6. PMID 15756448.
- Jung C, Kim RS, Zhang H, et al. (2005). "HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation.". Br. J. Cancer 92 (12): 2233–9. DOI:10.1038/sj.bjc.6602631. PMC 2361828. PMID 15928669. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2361828.
- Symmans WF (2006). "Genomic testing for sensitivity of breast cancer to hormonal therapy.". Clin. Cancer Res. 12 (7 Pt 1): 1954–5. DOI:10.1158/1078-0432.CCR-06-0289. PMID 16609001.
- Goetz MP, Suman VJ, Ingle JN, et al. (2006). "A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen.". Clin. Cancer Res. 12 (7 Pt 1): 2080–7. DOI:10.1158/1078-0432.CCR-05-1263. PMID 16609019.
- Cazal C, Sobral AP, de Almeida FC, et al. (2006). "The homeobox HOXB13 is expressed in human minor salivary gland.". Oral diseases 12 (4): 424–7. DOI:10.1111/j.1601-0825.2005.01218.x. PMID 16792730.
- Ma XJ, Hilsenbeck SG, Wang W, et al. (2006). "The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.". J. Clin. Oncol. 24 (28): 4611–9. DOI:10.1200/JCO.2006.06.6944. PMID 17008703.
- Muthusamy V, Duraisamy S, Bradbury CM, et al. (2007). "Epigenetic silencing of novel tumor suppressors in malignant melanoma.". Cancer Res. 66 (23): 11187–93. DOI:10.1158/0008-5472.CAN-06-1274. PMID 17145863.
- Miao J, Wang Z, Provencher H, et al. (2007). "HOXB13 promotes ovarian cancer progression.". Proc. Natl. Acad. Sci. U.S.A. 104 (43): 17093–8. DOI:10.1073/pnas.0707938104. PMC 2040435. PMID 17942676. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2040435.
- Ewing C, et al. (2012). "Germline mutations in HOXB13 and prostate cancer risk.". New Engl J Med 366 (2): 141–9. PMID 22236224.
|
||||||||
External links [link]
- HOXB13+protein,+human at the US National Library of Medicine Medical Subject Headings (MeSH)
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
 |
This article on a gene on chromosome 17 is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
https://wn.com/HOXB13
Human Genome Organisation
The Human Genome Organisation (HUGO) is an organization involved in the Human Genome Project, a project about mapping the human genome. HUGO was established in 1989 as an international organization, primarily to foster collaboration between genome scientists around the world. The HUGO Gene Nomenclature Committee (HGNC), sometimes referred to as "HUGO", is one of HUGO's most active committees and aims to assign a unique gene name and symbol to each human gene.
History
HUGO was established in late April 1988 at the first meeting dedicated to genome mapping at Cold Spring Harbor. The idea of starting the organization stemmed from a South African biologist by the name of Sydney Brenner, who is known for his significant contributions to work on the genetic code and other areas of molecular biology, as well as winning the Nobel prize in Physiology of Medicine in 2002. A Founding Council was elected at the meeting that total 42 scientists from 17 different countries. HUGO is grounded in Geneva Switzerland, and later went on to elect an additional 178 members, bringing the total up to 220.
This page contains text from Wikipedia, the Free Encyclopedia - https://wn.com/Human_Genome_Organisation
Podcasts:
PLAYLIST TIME: